バイオベッターの世界市場レポート 2025年

バイオベッター市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は11.7％で、1,182億米ドルに成長します。予測期間の成長は、バイオテクノロジーの進歩、個別化医療の重視の高まり、バイオ医薬品企業のパイプラインの拡大、慢性疾患の有病率の上昇、有利な規制状況、研究開発への投資の高まり、医療インフラの進歩などに起因すると考えられます。予測期間における主要動向には、新規テーマの開発、タンパク質工学と合理的設計、治療領域への注力、先進的医療インフラ、次世代シーケンス（NGS）技術の開発、高性能スクリーニング（HTS）技術の進歩などがあります。

慢性腎臓病（CKD）の有病率の増加は、バイオベッター市場の成長を促進すると予想されます。CKDは腎機能障害を引き起こす長期的な病態であり、最終的には腎不全を引き起こします。CKD患者の増加は、人口の高齢化、糖尿病や高血圧の割合の増加、食生活の乱れ、座りっぱなしのライフスタイル、環境汚染、診断技術の向上などに起因しています。バイオベッターは、もともとの生物製剤に比べ、有効性が向上し、副作用が少なく、投与方法が改善され、安定性が向上しているため、CKDを管理し、患者の予後を改善するための効果的な選択肢となっています。例えば、2023年6月、オックスFord大学出版局の研究プラットフォームであるOxford Academicは、英国におけるCKD有病率が2022～2032年の間に827万人から861万人へと4％増加すると予測しました。2032年におけるステージによる分布は、ステージ1が30.36％、ステージ2が21.07％、ステージ3aが29.78％、ステージ3bが11.86％、ステージ4が4.15％、ステージ5が2.78％と予想されています。その結果、慢性腎臓病の罹患率の上昇がバイオベッター市場の成長を牽引しています。

自己免疫疾患の有病率の上昇は、バイオベッター市場の成長を促進すると予測されています。自己免疫疾患は、免疫系が誤って健康な細胞を攻撃することで発生します。これらの疾患の発生率の増加は、遺伝的素因、環境の影響、ライフスタイルの変化などの要因に起因しています。バイオベッターは、当初の生物製剤に比べ、有効性の向上、副作用の軽減、投与レジメンの改善、安定性の向上を実現し、自己免疫疾患の治療においてより効果的で忍容性の高い製剤となっています。例えば、2023年12月、公衆衛生に重点を置く政府機関であるオーストラリア保健福祉ラボ（AIHW）は、2023年には関節リウマチが総疾患負担の2.0％を占めると報告しました。2021年、この疾患による死亡者数は1,145人で、これは人口10万人あたり3.2人の死亡に相当し、全死亡者数の0.7％を占めます。さらに2023年9月、カナダのIBD臨床研究センターが発表した「IBDの影響レポート2023」によると、カナダでは32万人以上が炎症性腸疾患（IBD）に罹患しており、2023年の有病率は人口10万人当たり825人であることが明らかになりました。有病率は毎年2.44％ずつ増加すると予測されており、2035年にはカナダ人口の1.1％、約47万人がIBDに罹患することになります。その結果、自己免疫疾患の有病率の増加がバイオベッター市場の拡大を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ののバイオベッターPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のバイオベッター市場：成長率分析
• 世界のバイオベッター市場の実績：規模と成長、2019～2024年
• 世界のバイオベッター市場の予測：規模と成長、2024～2029年、2034年
• 世界ののバイオベッター総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバイオベッター市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• エリスロポエチンバイオベッター
• 顆粒球コロニー刺激因子（G-CSF）バイオリアクタ
• インターフェロンバイオベッター
• インスリンバイオベッター
• モノクローナル抗体バイオベッター
• 抗血友病因子
• その他
• 世界のバイオベッター市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 皮下
• 吸入
• 静脈内
• その他のルート
• 世界のバイオベッター市場：疾患適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 糖尿病
• がん
• 腎臓病
• 神経変性疾患
• 遺伝性疾患-血友病
• その他
• 世界のバイオベッター市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のバイオベッター市場、エリスロポエチンバイオベターのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ダルベポエチンアルファ
• 持続的エリスロポエチン受容体活性化因子（CERA）
• 世界のバイオベッター市場顆粒球コロニー刺激因子（G-CSF）バイオベターのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ペグフィルグラスチム
• リペグフィルグラスチム
• 世界のバイオベッター市場、インターフェロンバイオベターのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ペグ化インターフェロンアルファ-2a
• ペグ化インターフェロンアルファ-2b
• 世界のバイオベッター市場、インスリンバイオベターのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 長時間作用型インスリンアナログ（インスリングラルギン）
• 速効型インスリンアナログ（インスリンアスパルト）
• 世界のバイオベッター市場、モノクローナル抗体バイオベターのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• トラスツズマブ（ハーセプチンバイオシミラー）
• ベバシズマブ（アバスチンバイオシミラー）
• リツキシマブ（リツキサンバイオシミラー）
• 世界のバイオベッター市場、抗血友病因子のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 組換え因子VIII（Nuwiq）
• 組換え第IX因子（アルプロリックス）
• 世界のバイオベッター市場、その他の薬剤クラスのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 成長因子
• サイトカイン
• 酵素補充療法
• ワクチン

第7章 地域別・国別分析

• 世界のバイオベッター市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のバイオベッター市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオベッター市場：競合情勢
• バイオベッター市場：企業プロファイル
  • Pfizer Inc.
  • Johnson & Johnson
  • Merck & Co Inc.
  • AbbVie Inc.
  • Bayer AG

第31章 その他の大手企業と革新的企業

• Sanofi Aventis LLC
• Bristol-Myers Squibb Company
• Novartis AG
• GlaxoSmithKline plc
• F Hoffmann La Roche Ltd.
• Eli Lilly and Co Ltd.
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc
• CSL Behring GmbH
• Biogen Inc.
• GRIFOLS USA LLC
• Celltrion Inc.
• Lonza Group AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• バイオベッター市場、2029年：新たな機会を提供する国
• バイオベッター市場、2029年：新たな機会を提供するセグメント
• バイオベッター市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Biobetters are biologic drugs that are similar to existing biologics but have been enhanced to offer improved efficacy, safety, or other clinical benefits. These enhancements may include better dosing regimens, reduced side effects, increased stability, or more convenient administration methods, providing a competitive edge over the original biologics.

The main drug classes of biobetters include erythropoietin biobetters, granulocyte-colony stimulating factor (G-CSF) biobetters, interferon biobetters, insulin biobetters, monoclonal antibody biobetters, antihemophilic factors, and others. Erythropoietin biobetters are enhanced versions of erythropoietin, a hormone that increases red blood cell production. Various routes of administration for biobetters include oral, subcutaneous, inhaled, and intravenous. These drugs address a range of disease indications such as diabetes, cancer, renal disease, neurodegenerative diseases, genetic disorders, and hemophilia. They are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The biobetters market research report is one of a series of new reports from The Business Research Company that provides biobetters market statistics, including biobetters industry global market size, regional shares, competitors with a biobetters market share, detailed biobetters market segments, market trends and opportunities, and any further data you may need to thrive in the biobetters industry. This biobetters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biobetters market size has grown rapidly in recent years. It will grow from $67.81 billion in 2024 to $75.98 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to increased understanding of disease mechanisms, growing healthcare expenditure, enhanced manufacturing technologies, technological innovations in drug delivery, advancements in protein engineering, increased demand for improved therapeutic efficacy.

The biobetters market size is expected to see rapid growth in the next few years. It will grow to $118.2 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advancements in biotechnology, growing emphasis on personalized medicine, expanding pipelines of biopharmaceutical companies, rising prevalence of chronic diseases, favorable regulatory landscapes, heightened investments in research and development, advance healthcare infrastructure. Major trends in the forecast period include development of novel biobetters, protein engineering and rational design, focus on therapeutic areas, advanced healthcare infrastructure, development of next-generation sequencing (NGS) technologies,advances in high-throughput screening (HTS) technologies.

The increasing prevalence of chronic kidney disease (CKD) is expected to drive the growth of the biobetters market. CKD is a long-term condition that leads to kidney dysfunction, ultimately causing kidney failure. The rise in CKD cases can be attributed to aging populations, higher rates of diabetes and hypertension, poor diet, sedentary lifestyles, environmental pollution, and improved diagnostic technologies. Biobetters offer enhanced efficacy, fewer side effects, better dosing regimens, and improved stability compared to original biologic treatments, making them an effective option for managing CKD and improving patient outcomes. For example, in June 2023, Oxford Academic, a research platform of Oxford University Press, projected a 4% increase in CKD prevalence in the UK, from 8.27 million to 8.61 million people between 2022 and 2032. The distribution across stages in 2032 is expected to be 30.36% for stage 1, 21.07% for stage 2, 29.78% for stage 3a, 11.86% for stage 3b, 4.15% for stage 4, and 2.78% for stage 5. As a result, the rising incidence of chronic kidney diseases is driving the growth of the biobetters market.

The rising prevalence of autoimmune diseases is anticipated to drive the growth of the biobetters market. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells. The increasing incidence of these conditions can be attributed to factors such as genetic predisposition, environmental influences, and lifestyle changes. Biobetters offer improved efficacy, fewer side effects, better dosing regimens, and enhanced stability compared to original biologic treatments, making them more effective and better tolerated for managing autoimmune disorders. For example, in December 2023, the Australian Institute of Health and Welfare (AIHW), a government agency focused on public health, reported that rheumatoid arthritis accounted for 2.0% of the total disease burden in 2023. In 2021, the condition caused 1,145 deaths, equivalent to 3.2 deaths per 100,000 people, representing 0.7% of all fatalities. Additionally, in September 2023, the Impact of IBD Report 2023 from the IBD Clinical and Research Centre in Canada highlighted that over 320,000 people in Canada suffer from inflammatory bowel disease (IBD), with a prevalence of 825 per 100,000 people in 2023. The prevalence is projected to increase by 2.44% annually, meaning that by 2035, 1.1% of the Canadian population, or around 470,000 people, will be living with IBD. As a result, the growing prevalence of autoimmune diseases is driving the expansion of the biobetters market.

Major companies in the biobetters market are developing biobetters for subcutaneous administration to improve patient convenience, enhance therapeutic outcomes, and reduce healthcare costs. Subcutaneous administration of biobetters offers a more convenient alternative to intravenous infusion, potentially improving patient compliance and healthcare delivery efficiency. For instance, in May 2023, Celltrion, a South Korean-based biopharmaceutical company, obtained approval from the Brazilian Health Regulatory Agency for their Remsima SC biobetters. This innovative biobetter version of their infliximab biosimilar, Remsima, is the world's only infliximab offering subcutaneous administration. Remsima SC improves upon a biosimilar by enhancing its accessibility and effectiveness, specifically indicated for inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. Remsima SC offers patients a more convenient and potentially more effective treatment option.

Major companies operating in the biobetters market are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, Sanofi Aventis LLC, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, F Hoffmann La Roche Ltd., Eli Lilly and Co Ltd., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc, CSL Behring GmbH, Biogen Inc., GRIFOLS USA LLC, Celltrion Inc., Lonza Group AG, Ionis Pharmaceuticals Inc., Incyte Corporation, Amicus Therapeutics Inc., Genentech Inc., Sun Pharmaceutical Industries

North America was the largest region in the biobetters market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biobetters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biobetters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biobetters market consists of sales of next-generation biologics, improved formulation products, and biosimilar drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biobetters Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biobetters market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biobetters ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biobetters market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Erythropoietin Biobetters; Granulocyte-Colony Stimulating Factor (G-CSF) Bioreactors; Interferon Biobetters; Insulin Biobetters; Monoclonal Antibodies Biobetters; Antihemophilic Factors; Other Drug Classes
• 2) By Route Of Administration: Oral; Subcutaneous; Inhaled; Intravenous; Other Routes
• 3) By Disease Indication: Diabetes; Cancer; Renal Disease; Neurodegenerative Diseases; Genetic Disorder-Hemophilia; Other Diseases
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Erythropoietin Biobetters: Darbepoetin Alfa; Continuous Erythropoietin Receptor Activator (CERA)
• 2) By Granulocyte-Colony Stimulating Factor (G-CSF) Biobetters: Pegfilgrastim; Lipegfilgrastim
• 3) By Interferon Biobetters: Pegylated Interferon Alfa-2a; Pegylated Interferon Alfa-2b
• 4) By Insulin Biobetters: Long-Acting Insulin Analogs (Insulin Glargine); Rapid-Acting Insulin Analogs (Insulin Aspart)
• 5) By Monoclonal Antibodies Biobetters: Trastuzumab (Herceptin Biosimilars); Bevacizumab (Avastin Biosimilars); Rituximab (Rituxan Biosimilars)
• 6) By Antihemophilic Factors: Recombinant Factor VIII (Nuwiq); Recombinant Factor IX (Alprolix)
• 7) By Other Drug Classes: Growth Factors; Cytokines; Enzyme Replacement Therapies; Vaccines
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biobetters Market Characteristics

3. Biobetters Market Trends And Strategies

4. Biobetters Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Biobetters Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biobetters PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biobetters Market Growth Rate Analysis
• 5.4. Global Biobetters Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biobetters Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biobetters Total Addressable Market (TAM)

6. Biobetters Market Segmentation

• 6.1. Global Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erythropoietin Biobetters
• Granulocyte-Colony Stimulating Factor (G-CSF) Bioreactors
• Interferon Biobetters
• Insulin Biobetters
• Monoclonal Antibodies Biobetters
• Antihemophilic Factors
• Other Drug Classes
• 6.2. Global Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Subcutaneous
• Inhaled
• Intravenous
• Other Routes
• 6.3. Global Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diabetes
• Cancer
• Renal Disease
• Neurodegenerative Diseases
• Genetic Disorder-Hemophilia
• Other Diseases
• 6.4. Global Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Biobetters Market, Sub-Segmentation Of Erythropoietin Biobetters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Darbepoetin Alfa
• Continuous Erythropoietin Receptor Activator (CERA)
• 6.6. Global Biobetters Market, Sub-Segmentation Of Granulocyte-Colony Stimulating Factor (G-CSF) Biobetters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pegfilgrastim
• Lipegfilgrastim
• 6.7. Global Biobetters Market, Sub-Segmentation Of Interferon Biobetters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pegylated Interferon Alfa-2a
• Pegylated Interferon Alfa-2b
• 6.8. Global Biobetters Market, Sub-Segmentation Of Insulin Biobetters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long-Acting Insulin Analogs (Insulin Glargine)
• Rapid-Acting Insulin Analogs (Insulin Aspart)
• 6.9. Global Biobetters Market, Sub-Segmentation Of Monoclonal Antibodies Biobetters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trastuzumab (Herceptin Biosimilars)
• Bevacizumab (Avastin Biosimilars)
• Rituximab (Rituxan Biosimilars)
• 6.10. Global Biobetters Market, Sub-Segmentation Of Antihemophilic Factors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Factor VIII (Nuwiq)
• Recombinant Factor IX (Alprolix)
• 6.11. Global Biobetters Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Growth Factors
• Cytokines
• Enzyme Replacement Therapies
• Vaccines

7. Biobetters Market Regional And Country Analysis

• 7.1. Global Biobetters Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biobetters Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biobetters Market

• 8.1. Asia-Pacific Biobetters Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biobetters Market

• 9.1. China Biobetters Market Overview
• 9.2. China Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biobetters Market

• 10.1. India Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biobetters Market

• 11.1. Japan Biobetters Market Overview
• 11.2. Japan Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biobetters Market

• 12.1. Australia Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biobetters Market

• 13.1. Indonesia Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biobetters Market

• 14.1. South Korea Biobetters Market Overview
• 14.2. South Korea Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biobetters Market

• 15.1. Western Europe Biobetters Market Overview
• 15.2. Western Europe Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biobetters Market

• 16.1. UK Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biobetters Market

• 17.1. Germany Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biobetters Market

• 18.1. France Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biobetters Market

• 19.1. Italy Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biobetters Market

• 20.1. Spain Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biobetters Market

• 21.1. Eastern Europe Biobetters Market Overview
• 21.2. Eastern Europe Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biobetters Market

• 22.1. Russia Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biobetters Market

• 23.1. North America Biobetters Market Overview
• 23.2. North America Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biobetters Market

• 24.1. USA Biobetters Market Overview
• 24.2. USA Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biobetters Market

• 25.1. Canada Biobetters Market Overview
• 25.2. Canada Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biobetters Market

• 26.1. South America Biobetters Market Overview
• 26.2. South America Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biobetters Market

• 27.1. Brazil Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biobetters Market

• 28.1. Middle East Biobetters Market Overview
• 28.2. Middle East Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biobetters Market

• 29.1. Africa Biobetters Market Overview
• 29.2. Africa Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biobetters Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biobetters Market Competitive Landscape And Company Profiles

• 30.1. Biobetters Market Competitive Landscape
• 30.2. Biobetters Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Biobetters Market Other Major And Innovative Companies

• 31.1. Sanofi Aventis LLC
• 31.2. Bristol-Myers Squibb Company
• 31.3. Novartis AG
• 31.4. GlaxoSmithKline plc
• 31.5. F Hoffmann La Roche Ltd.
• 31.6. Eli Lilly and Co Ltd.
• 31.7. Gilead Sciences Inc.
• 31.8. Amgen Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Regeneron Pharmaceuticals Inc
• 31.11. CSL Behring GmbH
• 31.12. Biogen Inc.
• 31.13. GRIFOLS USA LLC
• 31.14. Celltrion Inc.
• 31.15. Lonza Group AG

32. Global Biobetters Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biobetters Market

34. Recent Developments In The Biobetters Market

35. Biobetters Market High Potential Countries, Segments and Strategies

• 35.1 Biobetters Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biobetters Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biobetters Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer